Inpixon
NASDAQ:XTIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inpixon
NASDAQ:XTIA
|
US |
|
V
|
Visa Inc
BMV:V
|
US |
|
Celyad Oncology SA
F:1C0
|
BE |
|
A
|
Asia Medical & Agricultural Laboratory & Research Center PCL
SET:AMARC
|
TH |
|
C
|
China Industrial Group Inc
OTC:CIND
|
US |
|
F
|
Forvia SE
XMUN:FAU
|
FR |
|
B
|
Banpu Power PCL
SET:BPP
|
TH |
|
C
|
Cementir Holding NV
XBER:3PC
|
IT |
|
N
|
Novatek PAO
LSE:NVTK
|
RU |
|
D
|
DR Horton Inc
XMUN:HO2
|
US |
|
B
|
BRP Inc
NASDAQ:DOOO
|
CA |
Wall St Price Targets
XTIA Price Targets Summary
Inpixon
According to Wall Street analysts, the average 1-year price target for
XTIA is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is XTIA's stock price target?
Price Target
5.1
USD
According to Wall Street analysts, the average 1-year price target for
XTIA is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
What is the Revenue forecast for Inpixon?
Projected CAGR
291%
Over the last 12 years, the compound annual growth rate for Revenue has been -2%. The projected CAGR for the next 3 years is 291%.